



FOR IMMEDIATE RELEASE

LabCorp Contacts:

Media: Pattie Kushner — 336-436-8263

Media@LabCorp.com

Investors: Clarissa Willett — 336-436-5076

Investor@LabCorp.com

LABCORP LAUNCHES RETURN TO WORK SERVICES FOR EMPLOYERS

Employers Now Have Access to LabCorp’s High-Quality COVID-19 Testing Capabilities Including Its New
Fingerstick Antibody Blood Test

BURLINGTON, N.C., May 14, 2020 — LabCorp (NYSE: LH) announced today it is launching a new return to work service for employers. Many U.S. companies have asked for LabCorp’s assistance as they implement their return to work strategies for the summer and fall. To meet this urgent demand, LabCorp Employer Services provides customized return to work solutions using LabCorp’s trained medical staff for employee check-in health questionnaires, temperature screens, and COVID-19 test collection at the employer site or offsite. The service gives employers access to LabCorp’s COVID-19 testing solutions including its at-home collection test kit, its new fingerstick antibody blood test, and in the fall, flu vaccination services.

“We have been helping keep people safe and healthy for 50 years and are uniquely positioned to assist employers in their return to work strategies,” Dr. Brian Caveney, chief medical officer and president of LabCorp Diagnostics. “Through science and research, LabCorp’s diagnostic testing capabilities set the industry standard in quality and accuracy. Employer Services is another example of our commitment to being an integral part of the solution to this health crisis.”

LabCorp’s new convenient fingerstick antibody blood test detects IgG antibodies to the virus that causes COVID-19 and provides highly specific results equivalent to LabCorp’s other antibody blood testing methods. Fingerstick IgG antibody testing provides a convenient way to test large numbers of employees as part of return to work programs.

LabCorp’s fingerstick, or dried blood spot, IgG antibody test is being provided as a laboratory developed test, and uses the EUROIMMUN test which received Emergency Use Authorization by the U.S. Food and Drug Administration. LabCorp completed independent validation studies on this testing. The COVID-19 IgG antibody blood test detects the presence of antibodies to the virus and can help determine if an individual may have been exposed to the virus. While antibody tests are helpful to understand if an individual has developed antibodies and a potential immune response, antibody testing should not be used as the sole basis to diagnose or exclude infection.

LabCorp Employer Services was previously called Wellness Corporate Solutions. In addition to LabCorp’s COVID-19 testing and flu vaccination services, LabCorp Employer Services offers comprehensive wellness

solutions, including biometric screening, occupational testing, and diagnostic services. For more information, visit [LabCorp's Employer Services COVID-19 page](#).

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than \$11.5 billion in 2019.

To learn more about LabCorp, visit www.LabCorp.com, and to learn more about LabCorp's Covance drug development business, visit www.Covance.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements with respect to clinical laboratory testing, the potential benefits of COVID-19 serological testing, our responses to and the expected future impacts of the COVID-19 pandemic, and the opportunities for future growth. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company's control, including without limitation, whether our response to the COVID-19 pandemic will prove effective, the impact of the COVID-19 pandemic on our business and financial condition, as well as on general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, the Company's satisfaction of regulatory and other requirements, patient safety issues, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company's ability to implement the Company's business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company's other filings with the SEC.



Fingerstick for COVID-19 IgG antibody test (Photo: LabCorp)



Temporal thermometer check (Photo: LabCorp)

###